Nov. 19, 2026 — Innovative Health, Inc. has announced that it has received its 52nd clearance from the U.S. Food and Drug Administration (FDA), clearing the company to reprocess the single-use OCTARAY Mapping Catheter. Originally manufactured by Biosense Webster, part of Johnson & Johnson MedTech, OCTARAY is an advanced catheter used in electrophysiology procedures to map the heart’s electrical activity. Innovative Health is the only reprocessing company cleared to reprocess the device.
The clearance expands the range of advanced technologies that hospitals can include in their electrophysiology reprocessing programs. For facilities using OCTARAY, it creates a new opportunity to reduce device costs and waste while continuing to use the mapping technology their clinicians have selected.
“As electrophysiology technology advances, reprocessing needs to advance with it,” said Rick Ferreira, CEO of Innovative Health. “Hospitals should be able to adopt sophisticated devices and continue to grow the savings available through reprocessing. Our OCTARAY clearance reflects the technical expertise and sustained investment required to make that possible.”
FDA Clearance
Obtaining FDA clearance to reprocess a single-use device requires extensive engineering, cleaning, and sterilization validation, and the development of testing and inspection procedures. Innovative Health’s narrow focus on cardiology and electrophysiology has enabled the company to build deep expertise in the technologies used in these labs and the requirements for their reuse.
The clearance follows Innovative Health’s recently announced The Reprocessing Performance Benchmark, a new report designed to help electrophysiology leaders evaluate their programs and identify opportunities for growth. Together, the benchmark and the OCTARAY clearance reflect Innovative Health’s commitment to expanding both the devices available for reprocessing and hospitals’ ability to realize the benefits.

November 03, 2026 
